The low P/S ratio of Enanta Pharmaceuticals may be justified...
The low P/S ratio of Enanta Pharmaceuticals may be justified by its declining revenue and poor growth outlook compared to the industry. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment